Aims: The introduction of immunotherapy in head and neck squamous cell carcinoma (HNSCC) raises the need for harmonization between different types of antibodies and immunohistochemistry platforms for evaluating the expression of (Programmed death-ligand 1) PD-L1 with Combined Positive Score (CPS) in this tumor. We compare the expression of PD-L1, using the CPS and two widely used antibody (22C3 pharma Dx and SP263 assay) in a cohort of HNSCC. Methods and results: We analyzed forty-three whole sections of HNSCC with two different anti-PD-L1 antibodies, 22C3 pharma Dx and SP263 assay. Results, expressed as CPS, were evaluated by ten trained pathologists and statistical analyses, including interobserver agreement, were performed. We found a very similar distribution for PD-L1 expression between 22C3 pharmaDx assay and SP263 assay in our cohort and a strong significant correlation between the two assays for all specimens (Spearman r= 0.945; p<0.0001). The interobserver reliability among pathologists for the continuous scores of CPS with ICC and the correlation between the two assays was both good. Moreover, the agreement rate between assays was high at all cut-offs and was best for the most relevant cut-off of CPS ≥1, while the kappa values were always in the range of almost perfect. Conclusions: Two different assays (22C3 pharmaDx assay and SP263 assay) for PD-L1 in HNSCC showed high agreement. This data suggests the interchangeability of these two antibodies in the selection of patients with HNSCC for immunotherapy.

Evaluating PD-L1 in head & neck squamous cell carcinoma: concordance between 22C3 PharmaDx and SP263 assays on whole sections from a multicenter study / Cerbelli, Bruna; Girolami, Ilaria; Eccher, Albino; Costarelli, Leopoldo; Taccogna, Silvia; Scialpi, Renzo; Benevolo, Maria; Lucante, Teresa; Alò, Piero Luigi; Stella, Francesca; Pignataro, Maria Gemma; Fadda, Guido; Perrone, Giuseppe; d'Amati, Giulia; Martini, Maurizio. - In: HISTOPATHOLOGY. - ISSN 0309-0167. - 80:2(2021), pp. 397-406. [10.1111/his.14562]

Evaluating PD-L1 in head & neck squamous cell carcinoma: concordance between 22C3 PharmaDx and SP263 assays on whole sections from a multicenter study

Cerbelli, Bruna
Primo
;
Pignataro, Maria Gemma;d'Amati, Giulia
Penultimo
;
2021

Abstract

Aims: The introduction of immunotherapy in head and neck squamous cell carcinoma (HNSCC) raises the need for harmonization between different types of antibodies and immunohistochemistry platforms for evaluating the expression of (Programmed death-ligand 1) PD-L1 with Combined Positive Score (CPS) in this tumor. We compare the expression of PD-L1, using the CPS and two widely used antibody (22C3 pharma Dx and SP263 assay) in a cohort of HNSCC. Methods and results: We analyzed forty-three whole sections of HNSCC with two different anti-PD-L1 antibodies, 22C3 pharma Dx and SP263 assay. Results, expressed as CPS, were evaluated by ten trained pathologists and statistical analyses, including interobserver agreement, were performed. We found a very similar distribution for PD-L1 expression between 22C3 pharmaDx assay and SP263 assay in our cohort and a strong significant correlation between the two assays for all specimens (Spearman r= 0.945; p<0.0001). The interobserver reliability among pathologists for the continuous scores of CPS with ICC and the correlation between the two assays was both good. Moreover, the agreement rate between assays was high at all cut-offs and was best for the most relevant cut-off of CPS ≥1, while the kappa values were always in the range of almost perfect. Conclusions: Two different assays (22C3 pharmaDx assay and SP263 assay) for PD-L1 in HNSCC showed high agreement. This data suggests the interchangeability of these two antibodies in the selection of patients with HNSCC for immunotherapy.
File allegati a questo prodotto
File Dimensione Formato  
Cerbelli_postprint_Evaluating PD-L1_2021.pdf

embargo fino al 08/09/2022

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 488.65 kB
Formato Adobe PDF
488.65 kB Adobe PDF Visualizza/Apri PDF
Cerbelli_Evaluating programmed_2022.pdf

accesso aperto

Note: https://onlinelibrary.wiley.com/doi/10.1111/his.14562?af=R
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.67 MB
Formato Adobe PDF
1.67 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1568042
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact